Recruiting

Observational Study

Sponsor:

Wake Forest University Health Sciences

Code:

NCT01890486

Conditions

Acute Myelogenous Leukemia

Acute Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Non-Hodgkin's Lymphoma

Hodgkin's Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

Conditions

Acute Myelogenous Leukemia

Acute Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Non-Hodgkin's Lymphoma

Hodgkin's Disease

Study ID

NCT01890486

Start date

May 21, 2001

Status verified date

Apr, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant

Exclusion Criteria:

Participation in any other treatment research protocol

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Data followup [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Dianna Howard, MD

dhoward@wakehealth.edu

Locations

Wake Forest Baptist Health

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

David Hurd, MD

336-716-2843dhurd@wakehealth.edu

Principal Investigator:

David Hurd, MD

More Information

Sponsor

Wake Forest University Health Sciences

Last update posted

Apr 13, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Wake Forest University Health Sciences on 2026-04-13.